The Latest Breaking News from Pfizer

Government advisers say it’s time to update the recipe for the COVID-19 vaccines Americans will receive in the fall

With a dividend yield of nearly 6%, pharma giant Pfizer is among the highest-yielding S&P 500 stocks. While the stock's price action has been disappointing like most other high-dividend stocks, it looks worth a bet given the tepid valuations.

Prolonged success boils down to a few subtle factors—but surprisingly, they don't include strategy, structure, technology, or even culture.

Fertilized hen eggs are still the main ingredient in making vaccines that may protect us against H5N1

The bird flu outbreak in U.S. dairy cows is prompting development of new, next-generation mRNA vaccines — akin to the shots deployed during the COVID-19 pandemic

A Pfizer medicine has been shown to greatly reduce cancer progression and improve survival outcomes for people in the advanced stages of a form of lung cancer, results published Friday showed.

While the U.S. Food and Drug Administration (FDA) and the officials from the CDC continue to investigate the risks, the current recommendation is to continue the vaccine as "the estimated benefits of RSV vaccination continued to outweigh potential risks."

CDC reports increased Guillain-Barre syndrome cases in older adults post-RSV vaccination, emphasizing benefits outweigh risks.

Reports of a rare nervous system disorder are “more common than expected” in older U.S. adults who got the new RSV vaccines

The pharma sector is primed for solid growth owing to technological advancements, growing healthcare needs, and a rise in chronic diseases. Given this backdrop, let’s analyze the fundamentals of pharmaceutical stocks Pfizer (PFE) and Bristol-Myers Squibb (BMY) to determine which of these stocks offer better dividend stability and growth. Read…

The former pharma laggard is in a race with Shell to be the first FTSE 100 stock to be valued at £200bn